Yuval  Cohen net worth and biography

Yuval Cohen Biography and Net Worth

Yuval Cohen serves as Chief Executive Officer, Director of the Company. Dr. Cohen has served as our Chief Executive Officer and as a director since April 11, 2014. Dr. Cohen joined Corbus Pharmaceuticals, Inc. (formerly JB Therapeutics, Inc.), our wholly-owned subsidiary, as its Chief Executive Officer in July 2013. Prior to joining Corbus Pharmaceuticals, Inc., he was the President and co-founder of Celsus Therapeutics PLC (“Celsus”) (Nasdaq CM: CLTX) from 2005 until February 2013, and as Senior Vice President from February 2013 until June 2013. Dr. Cohen was also a board member of Celsus until December 2013. Starting as a small startup with seed financing, under Dr. Cohen’s leadership, Celsus developed five novel anti-inflammatory drug candidates with two reaching Phase IIb stages focusing on allergies and autoimmune diseases of the skin (eczema), airways (cystic fibrosis and hay fever), digestive tract (inflammatory bowel disease) and eye (conjunctivitis). Dr. Cohen participated in all stages of the pre-clinical and clinical development from project management to interactions with regulatory bodies and with the investment community in fundraising. Apart from his industry experience, he is also the author of a number of peer-reviewed papers and reviews as well as listed inventor on a number of patents. Dr. Cohen holds a BSc (Hons) in microbiology and biochemistry from University of Cape Town, South Africa, and has a Ph.D., summa cum laude, from the Curie Institute of Cancer Research in Paris and the University of Paris V. Dr. Cohen was selected as a director because of his business and leadership experience in the biopharmaceutical sector, as well as a result of having served as a director since our inception.

What is Yuval Cohen's net worth?

The estimated net worth of Yuval Cohen is at least $3.70 million as of June 17th, 2024. Dr. Cohen owns 84,400 shares of Corbus Pharmaceuticals stock worth more than $3,697,564 as of June 19th. This net worth evaluation does not reflect any other investments that Dr. Cohen may own. Additionally, Dr. Cohen receives a salary of $907,780.00 as CEO at Corbus Pharmaceuticals. Learn More about Yuval Cohen's net worth.

How old is Yuval Cohen?

Dr. Cohen is currently 49 years old. There are 1 older executives and no younger executives at Corbus Pharmaceuticals. Learn More on Yuval Cohen's age.

What is Yuval Cohen's salary?

As the CEO of Corbus Pharmaceuticals Holdings, Inc., Dr. Cohen earns $907,780.00 per year. Learn More on Yuval Cohen's salary.

How do I contact Yuval Cohen?

The corporate mailing address for Dr. Cohen and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Yuval Cohen's contact information.

Has Yuval Cohen been buying or selling shares of Corbus Pharmaceuticals?

During the past quarter, Yuval Cohen has sold $1,981,793.95 of Corbus Pharmaceuticals stock. Most recently, Yuval Cohen sold 11,103 shares of the business's stock in a transaction on Monday, June 17th. The shares were sold at an average price of $46.02, for a transaction totalling $510,960.06. Following the completion of the sale, the chief executive officer now directly owns 84,400 shares of the company's stock, valued at $3,884,088. Learn More on Yuval Cohen's trading history.

Are insiders buying or selling shares of Corbus Pharmaceuticals?

During the last twelve months, Corbus Pharmaceuticals insiders bought shares 3 times. They purchased a total of 1,282,632 shares worth more than $33,374,555.68. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 51,733 shares worth more than $2,530,798.76. The most recent insider tranaction occured on June, 18th when CFO Sean F Moran sold 1,958 shares worth more than $82,470.96. Insiders at Corbus Pharmaceuticals own 4.0% of the company. Learn More about insider trades at Corbus Pharmaceuticals.

Information on this page was last updated on 6/18/2024.

Yuval Cohen Insider Trading History at Corbus Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/17/2024Sell11,103$46.02$510,960.0684,400View SEC Filing Icon  
6/14/2024Sell29,317$50.17$1,470,833.8984,400View SEC Filing Icon  
8/10/2022Buy3,800$0.26$988.0098,230View SEC Filing Icon  
5/16/2022Buy10,500$0.25$2,625.0094,430View SEC Filing Icon  
3/9/2022Buy8,600$0.37$3,182.00View SEC Filing Icon  
11/11/2020Buy4,240$1.21$5,130.4075,330View SEC Filing Icon  
11/11/2020Buy4,240$1.21$5,130.4075,330View SEC Filing Icon  
11/12/2019Buy1,430$4.26$6,091.8066,790View SEC Filing Icon  
8/12/2019Buy1,175$6.06$7,120.5065,360View SEC Filing Icon  
5/13/2019Buy995$6.99$6,955.0564,185View SEC Filing Icon  
3/14/2019Buy1,530$6.49$9,929.7063,190View SEC Filing Icon  
5/15/2018Buy1,725$5.85$10,091.2561,660View SEC Filing Icon  
3/14/2018Buy1,160$6.89$7,992.4059,935View SEC Filing Icon  
11/10/2017Buy1,000$7.17$7,170.0058,775View SEC Filing Icon  
8/11/2017Buy1,695$6.00$10,170.0057,775View SEC Filing Icon  
5/11/2017Buy3,250$6.01$19,532.5056,080View SEC Filing Icon  
11/22/2016Buy1,340$7.64$10,237.6012,830View SEC Filing Icon  
6/6/2016Buy1,500$3.34$5,010.0011,490View SEC Filing Icon  
5/18/2016Buy2,125$2.40$5,100.009,990View SEC Filing Icon  
8/17/2015Buy2,100$1.92$4,032.00View SEC Filing Icon  
12/3/2014Buy1,000$3.20$3,200.00View SEC Filing Icon  
See Full Table

Yuval Cohen Buying and Selling Activity at Corbus Pharmaceuticals

This chart shows Yuval Cohen's buying and selling at Corbus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals logo
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Read More

Today's Range

Now: $43.81
Low: $40.61
High: $43.98

50 Day Range

MA: $42.38
Low: $33.50
High: $52.89

2 Week Range

Now: $43.81
Low: $3.03
High: $55.41

Volume

418,829 shs

Average Volume

237,723 shs

Market Capitalization

$468.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.52